Journals / Anadolu Kardiyoloji Dergisi / 2007 / Cilt: 7 - Sayı: 1

Antithrombotic therapy in atrial fibrillation with ximelagatran: Can it be an alternative to warfarin?

Atriyal fibrilasyonda ximelagatran ile antitrombotik tedavi: Ximelagatran warfarin’e alternatif olabilir mi?

Pages
54–58
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Although it seems as a promising option for the prevention and therapy of thromboembolism, its safety and efficacy need to be determined definitely by further clinical trials.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Nonvalvular atrial fibrillation is the most common cardiac arrhythmia associated with a substantial risk of thromboembolism and stroke.
📊
Key Findings & Data:Despite numerous disadvantages that limit its efficacy and safety, warfarin is widely used in the prevention and treatment of thromboembolism related with atrial fibrillation.
💡
Conclusion & Impact:Although it seems as a promising option for the prevention and therapy of thromboembolism, its safety and efficacy need to be determined definitely by further clinical trials.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Nonvalvular atrial fibrillation is the most common cardiac arrhythmia associated with a substantial risk of thromboembolism and stroke. Despite numerous disadvantages that limit its efficacy and safety, warfarin is widely used in the prevention and treatment of thromboembolism related with atrial fibrillation. Ximelagatran, an oral direct thrombin inhibitor has the potential to be an alternative choice in the prevention and therapy of thromboembolism related with atrial fibrillation. Studies compared ximelagatran with warfarin in nonvalvular atrial fibrillation at risk for stroke showed that fixed dose oral ximelagatran is effective as adjusted dose warfarin in stroke prevention. Ximelagatran has numerous advantages over warfarin in clinical practice. Although it seems as a promising option for the prevention and therapy of thromboembolism, its safety and efficacy need to be determined definitely by further clinical trials.

Özet

Valvüler olmayan atriyal fibrilasyon, artmış tromboemboli ve inme riski ile birlikte seyreden en sık karşılaşılan kardiyak aritmidir. Warfarin, etkinlik ve güvenirliliğini sınırlayan birçok dezavantajlarına rağmen, atriyal fibrilasyonla ilişkili tromboembolinin önlenmesi ve tedavisinde yaygın olarak kullanılmaktadır. Bir oral direkt trombin inhibitörü olan ximelagatran, atriyal fibrilasyon ile ilişkili olan tromboembolinin tedavi ve önlenmesinde alternatif bir seçenek olma potansiyeline sahiptir. İnme riskine sahip atriyal fibrilasyonlu hastalarda ximelagatran ile warfarinin karşılaştırıldığı çalışmalarda, sabit dozda uygulanan oral ximelagatranın inmenin önlenmesinde ayarlanmış dozda warfarin kadar etkin olduğu gösterilmiştir. Klinik uygulamada ximelagatran warfarine karşı potansiyel üstünlüklere sahiptir. Ximelagatran tromboembolinin önlenmesi ve tedavisinde umut veren bir seçenek gibi görünse de etkinlik ve güvenirliliğin kesin olarak belirlenmesi için daha ileri çalışmalara ihtiyaç vardır.

🔖

Cite This Article

MADEN, O., SELÇUK, M. T., SELÇUK, H. (2022). Antithrombotic therapy in atrial fibrillation with ximelagatran: Can it be an alternative to warfarin?. Anadolu Kardiyoloji Dergisi, Cilt: 7 - Sayı: 1, 54–58. https://ajindex.com/articles/437154

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Hart RG. Atrial fibrillation and stroke prevention. N Engl J Med 2003; 349: 1015-6
  2. Berry C, Alan R, Taylor J, Brady AJ. Atrial fibrillation in the elderly. Br J Cardiol 2003; 10: 373-8
  3. Albers GW, Dalen JE, Laupacis A, Manning WJ, Petersen P, Singer DE. Antithrombotic therapy in atrial fibrillation. Chest 2001; 119 (1 Suppl): 194-206
  4. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22: 983-8
  5. Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: the Framingham study.N Engl J Med 1982;306:1018-22
  6. Gerdts E, Oikarinen L, Palmieri V, Otterstad JE, Wachtell K, Boman K. Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. Correlates of left atrial size in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. Hypertension 2002; 39: 739-43
  7. Kamath S, Lip GY. Atrial fibrillation in the elderly: anticoagulation strategies and indications in the very elderly. Am J Geriatr Cardiol 2002; 11: 357-62
  8. Hamaad A, Tayebjee MH, Lip GYH. Ximelagatran: The future in anticoagulation practice. Br J Cardiol 2004; 11: 229-34
  9. Kumagai K, Fukunami M, Kitabatake A, Kamada T, Hoki N. Increased cardiovascular clotting in patients with chronic atrial fibrillation. J Am Coll Cardiol 1990; 16: 377–80
  10. Sohara H, Amitani S, Kurose M, Miyahara K. Atrial fibrillation activates platelets and coagulation in a time-dependent manner: a study of patients with paroxysmal atrial fibrillation. J Am Coll Cardiol 1997; 29: 106–12
  11. Blann AD, Lip GY. Hypothesis: is soluble P-selectin a new marker of platelet activation? Atherosclerosis 1997; 128: 135–8
  12. Lip GY, Blann A. von Willebrand factor: a marker of endothelial dysfunction in vascular disorders? Cardiovasc Res 1997; 34: 255–65
  13. Sabatini T, Frisoni GB, Barbisoni P, Bellelli G, Rozzini R, Trabucchi M. Atrial fibrillation and cognitive disorders in older people. J Am Geriatr Soc 2000; 48: 387-90
  14. Ezekowitz MD, James KE, Nazarian SM, Davenport J, Broderick JP, Gupta SR. Silent cerebral infarction in patients with nonrheumatic atrial fibrillation. The Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. Circulation 1995; 92: 2178-82
  15. Raiha I, Tarvonen S, Kurki T, Rajala T, Sourander L. Relationship between vascular factors and white matter low